Diabetic neuropathy mainly comprises distal symmetric polyneuropathy, leading to sensory loss, pain, and motor dysfunction, and can result in diabetic foot ulcers requiring lower-limb amputations
Potential explanations include differences in the type of patients included, adherence to study treatment, sample size, duration of drug exposure, and GLP1 receptor activation with greater HbA1c reduction with longer-acting human GLP1-based analogs than with some short-acting exendin-4 analogs
The lack of effect of a metabolic drug targeting the TME in clinical trials may be attributed to the fact that most inhibitors are screened in single cell cultures and homogenous tumor models
Incidence of evolution to lentigo maligna melanoma is low, about 2.2% to 5% in elderly patients
Full details of those programs have not yet been released by CMS